These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 28431262)

  • 1. Immunologic approaches for the treatment of multiple myeloma.
    Rasche L; Weinhold N; Morgan GJ; van Rhee F; Davies FE
    Cancer Treat Rev; 2017 Apr; 55():190-199. PubMed ID: 28431262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel immunotherapies.
    Yi Q
    Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: Immunotherapy in Multiple Myeloma.
    Giuliani N; Malavasi F
    Front Immunol; 2019; 10():1945. PubMed ID: 31475006
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
    Morandi F; Horenstein AL; Costa F; Giuliani N; Pistoia V; Malavasi F
    Front Immunol; 2018; 9():2722. PubMed ID: 30546360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
    Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
    Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody therapies for multiple myeloma.
    Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
    Expert Opin Biol Ther; 2020 Mar; 20(3):295-303. PubMed ID: 31944131
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopathogenesis and immunotherapy of multiple myeloma.
    Tamura H
    Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
    Karp Leaf R; Cho HJ; Avigan D
    Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
    Drent E; Themeli M; Poels R; de Jong-Korlaar R; Yuan H; de Bruijn J; Martens ACM; Zweegman S; van de Donk NWCJ; Groen RWJ; Lokhorst HM; Mutis T
    Mol Ther; 2017 Aug; 25(8):1946-1958. PubMed ID: 28506593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could daratumumab be used to treat severe allergy?
    Blankestijn MA; van de Donk NWCJ; Sasser K; Knulst AC; Otten HG
    J Allergy Clin Immunol; 2017 May; 139(5):1677-1678.e3. PubMed ID: 28109726
    [No Abstract]   [Full Text] [Related]  

  • 20. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
    Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
    Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.